# Bonesupport Holding > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/bonesupportholding). ## Overview BONESUPPORT Holding AB is a Swedish parent company for a medical technology group focused on orthobiologics. The group develops and commercializes injectable bioceramic bone graft substitutes under the CERAMENT platform for use in orthopedic procedures, with sales concentrated in the US and Europe. ## Products & services • CERAMENT BVF bone graft substitute • CERAMENT G antibiotic-eluting bone graft substitute • CERAMENT V antibiotic-eluting bone graft substitute • Orthopedic infection and bone defect treatment solutions • Clinical and medical education support for surgeons - **CERAMENT bone graft substitutes** (90%) — Injectable bioceramic bone graft products used to fill bone voids and remodel into host bone. - **Antibiotic-eluting products** (70%) — CERAMENT G and CERAMENT V products designed for bone infection and contaminated cases. - **Non-antibiotic bone void filler** (10%) — CERAMENT BVF used in orthopedic reconstruction where drug elution is not required. - **Commercial and clinical support** (10%) — Training, evidence generation, and surgeon support that help adoption of CERAMENT. - CERAMENT BVF bone graft substitute - CERAMENT G antibiotic-eluting bone graft substitute - CERAMENT V antibiotic-eluting bone graft substitute - Orthopedic infection and bone defect treatment solutions - Clinical and medical education support for surgeons ## Customers BONESUPPORT sells primarily to hospitals, orthopedic surgeons, and healthcare systems that treat bone defects, fractures, and bone infections. In the US, sales are made both directly and through distributors, including OrthoPediatrics for pediatric access, while in Europe the company uses a mix of direct sales, hybrid coverage, and specialist distributors. Demand is tied to adoption in specific orthopedic procedures such as trauma, foot and ankle, revision arthroplasty, and spine. - **Hospitals and surgical centers** (primary) — Buy CERAMENT for orthopedic procedures involving bone voids, trauma, and infection management. - **Orthopedic surgeons** (primary) — Use the products in surgery and influence adoption based on clinical outcomes and evidence. - **Pediatric hospitals** (secondary) — Access CERAMENT through OrthoPediatrics for children’s orthopedic cases. - **Distributors and agents** (secondary) — Purchase or facilitate sales in selected markets to extend geographic reach and coverage. - Hospitals and surgical centers treating bone defects and infections - Orthopedic surgeons using CERAMENT in trauma and reconstruction cases - Pediatric hospital networks accessed through OrthoPediatrics - Distributors and agents that support end-customer reach in some markets - Healthcare systems that value clinical evidence and single-stage procedures ## Geography BONESUPPORT is headquartered in Lund, Sweden and operates through subsidiaries across Europe and the US. The company’s commercial footprint is concentrated in the US and major European markets such as Germany, the UK, Sweden, Denmark, and Benelux, with additional coverage in Australia, Canada, Italy, Norway, Spain, South Africa, and other ROW markets. Geography matters because the business relies on local sales coverage, distributor relationships, and regulatory access in each market. - **Europe & Rest of the World** — The excerpt provides regional operating coverage but not a revenue split. - Headquartered in Lund, Sweden with a Swedish parent company structure - Core commercial markets are the US and major European orthopedic markets - Own sales teams in Germany, the UK, Sweden, Denmark and Benelux - Hybrid model in Australia, Canada, Italy, Norway, Spain and South Africa - Specialist distributors cover other European and rest-of-world markets ## Strategy BONESUPPORT’s strategy centers on expanding CERAMENT adoption in prioritized orthopedic segments, especially Foot & Ankle, Trauma, Revision Arthroplasty, and Spine. The company also emphasizes clinical and health-economic evidence, commercial execution, and preparation for new indications to broaden the platform over time. - **Segment focus in orthopedic procedures** (short-term) — Concentrating on high-value procedure areas improves sales efficiency and clinical relevance. - **Launch and expand in Spine** (medium-term) — Spine extends the CERAMENT platform into another large orthopedic use case. - **Evidence generation and medical education** (medium-term) — Clinical publications and health-economic data support surgeon adoption and reimbursement discussions. - Focus commercial resources on Foot & Ankle, Trauma, and Revision Arthroplasty - Prepare for launch in Spine to expand the addressable market - Build clinical and health-economic evidence to support adoption - Increase geographic penetration in established and emerging markets - Use a direct-plus-distributor model to balance reach and control ## Risks BONESUPPORT is exposed to adoption risk because its products depend on surgeon acceptance, clinical evidence, and reimbursement dynamics in orthopedic care. The company also faces regulatory, intellectual property, product liability, currency, and tariff-related risks typical for a medical device business with international sales and cross-border supply chains. - **Slow market acceptance of CERAMENT** [high] — Revenue depends on surgeons and hospitals adopting a new orthopedic treatment standard. - **Regulatory and product approval risk** [high] — Medical device and combination-product requirements can delay or block launches. - **Product liability and insurance risk** [high] — Implantable orthopedic products can create claims if outcomes or safety are challenged. - **Intellectual property risk** [medium] — CERAMENT depends on patents and protection against competing products or disputes. - **Foreign exchange risk** [medium] — Revenues and expenses are denominated mainly in USD, GBP and EUR versus SEK reporting. - **Tariff and trade risk** [medium] — US import tariffs can increase cost of goods and reduce segment economics. - Market adoption can take time, delaying revenue generation - Regulatory approval and compliance are required for medical device launches - Patent and IP disputes could affect product protection - Product liability claims could arise if safety issues occur - Currency swings affect reported results because sales are in USD, GBP and EUR - US import tariffs can pressure gross margin on imported goods ## Accounting Revenue is recognized when control of CERAMENT products transfers to the customer, which makes distributor arrangements and return rights important judgment areas. The company also has meaningful estimates around trade receivables, tax loss carryforwards, leases, share-based remuneration, and derivative fair values linked to share swap programs. Because sales are international and product mix includes direct and agent-based channels, timing of revenue, commissions, and foreign exchange effects can materially affect reported results. - **Revenue recognition and channel assessment** — Sales commissions and fees, revenue timing - **Right of return provisions** — Revenue and provisions - **Share-based remuneration and derivatives** — Operating expenses and financial items - **Lease accounting** — Balance sheet and depreciation/interest expense - **Tax loss carryforwards and receivables** — Tax assets and impairment allowances - Point-in-time revenue recognition for CERAMENT product sales - Distributor vs agent assessment affects gross revenue and commissions - Right-of-return estimates matter for OrthoPediatrics sales - Share-based remuneration and share swaps require fair value accounting - Lease liabilities depend on borrowing-rate estimates - Trade receivables and tax loss carryforwards require judgment --- *Last updated: 2026-08-11T04:04:51.315676+00:00*